USD 5.13
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.18 Billion EUR | 6.1% |
2022 | 1.21 Billion EUR | 16.4% |
2021 | 922.27 Million EUR | -29.71% |
2020 | 1.29 Billion EUR | -8.78% |
2019 | 1.42 Billion EUR | 23.48% |
2018 | 1.22 Billion EUR | 0.98% |
2017 | 1.28 Billion EUR | 4.61% |
2016 | 1.14 Billion EUR | 0.01% |
2015 | 1.16 Billion EUR | 11.07% |
2014 | 1.04 Billion EUR | 21.86% |
2013 | 864.58 Million EUR | 6.86% |
2012 | 776.26 Million EUR | 111.56% |
2011 | 341.42 Million EUR | 54.66% |
2010 | 233.65 Million EUR | -6.12% |
2009 | 255.94 Million EUR | 5.48% |
2008 | 243.67 Million EUR | 27.77% |
2007 | 190.71 Million EUR | 117.48% |
2006 | 100.94 Million EUR | 35.77% |
2005 | 75.99 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 347.53 Million EUR | 3.86% |
2024 Q2 | 364.51 Million EUR | 4.89% |
2023 Q2 | 252.84 Million EUR | -10.89% |
2023 Q3 | 250.52 Million EUR | -0.92% |
2023 FY | - EUR | 6.1% |
2023 Q1 | 283.74 Million EUR | 195.81% |
2023 Q4 | 331.57 Million EUR | 32.35% |
2022 Q1 | 250.97 Million EUR | 147.8% |
2022 FY | - EUR | 16.4% |
2022 Q4 | 95.92 Million USD | -52.35% |
2022 Q3 | 201.32 Million EUR | -23.78% |
2022 Q2 | 264.12 Million EUR | 5.24% |
2021 Q1 | 286.15 Million EUR | -23.6% |
2021 Q3 | 101.28 Million EUR | -69.16% |
2021 Q2 | 328.36 Million EUR | 14.75% |
2021 FY | - EUR | -29.71% |
2021 Q4 | 101.28 Million USD | 0.0% |
2020 Q3 | 448.51 Million EUR | 112.46% |
2020 FY | - EUR | -8.78% |
2020 Q1 | 350.35 Million EUR | -3.18% |
2020 Q2 | 211.11 Million EUR | -39.74% |
2020 Q4 | 374.52 Million EUR | -16.5% |
2019 Q2 | 385.53 Million EUR | 26.17% |
2019 Q4 | 361.87 Million EUR | 0.68% |
2019 FY | - EUR | 23.48% |
2019 Q1 | 305.56 Million EUR | 5.65% |
2019 Q3 | 359.41 Million EUR | -6.78% |
2018 Q2 | 312.61 Million EUR | 5.84% |
2018 Q1 | 295.37 Million EUR | 47.77% |
2018 FY | - EUR | 0.98% |
2018 Q3 | 307.53 Million EUR | -1.62% |
2018 Q4 | 289.23 Million EUR | -5.95% |
2017 FY | - EUR | 4.61% |
2017 Q4 | 199.88 Million EUR | -42.12% |
2017 Q3 | 345.35 Million EUR | 4.52% |
2017 Q2 | 330.42 Million EUR | 7.97% |
2017 Q1 | 306.02 Million EUR | 5.11% |
2016 Q1 | 281.41 Million EUR | -5.03% |
2016 Q2 | 284.69 Million EUR | 1.17% |
2016 Q3 | 284.88 Million EUR | 0.07% |
2016 FY | - EUR | 0.01% |
2016 Q4 | 291.13 Million EUR | 2.2% |
2015 Q3 | 291.18 Million EUR | 3.8% |
2015 Q1 | 273.94 Million EUR | -0.51% |
2015 FY | - EUR | 11.07% |
2015 Q2 | 280.53 Million EUR | 2.41% |
2015 Q4 | 296.3 Million EUR | 1.76% |
2014 Q4 | 275.35 Million EUR | 6.9% |
2014 FY | - EUR | 21.86% |
2014 Q3 | 257.58 Million EUR | 11.49% |
2014 Q2 | 231.04 Million EUR | -12.52% |
2014 Q1 | 264.11 Million EUR | 35.43% |
2013 Q4 | 195.01 Million EUR | -9.2% |
2013 FY | - EUR | 6.86% |
2013 Q1 | 215.92 Million EUR | 43.8% |
2013 Q2 | 217.92 Million EUR | 0.93% |
2013 Q3 | 214.78 Million EUR | -1.44% |
2012 Q3 | 204.9 Million EUR | 2.98% |
2012 Q2 | 198.97 Million EUR | -3.01% |
2012 Q1 | 205.15 Million EUR | 60.24% |
2012 FY | - EUR | 111.56% |
2012 Q4 | 150.15 Million EUR | -26.72% |
2011 Q3 | 147.23 Million EUR | 341.96% |
2011 Q4 | 128.03 Million EUR | -13.04% |
2011 FY | - EUR | 54.66% |
2011 Q1 | 64.52 Million EUR | 86.4% |
2011 Q2 | 33.31 Million EUR | -48.37% |
2010 FY | - EUR | -6.12% |
2010 Q4 | 34.61 Million EUR | -48.15% |
2010 Q3 | 66.76 Million EUR | 0.0% |
2009 FY | - EUR | 5.48% |
2008 FY | - EUR | 27.77% |
2007 FY | - EUR | 117.48% |
2006 FY | - EUR | 35.77% |
2005 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
AstraZeneca PLC | 13.28 Billion USD | 91.106% |
Bristol-Myers Squibb Company PFD CONV 2 | 19.41 Billion USD | 93.913% |
CSPC Pharmaceutical Group Limited | 1.14 Billion USD | -2.955% |
Clarus Therapeutics Holdings, Inc. | -39.7 Million USD | 3076.945% |
Novartis AG | 19.51 Billion USD | 93.944% |
PT Kalbe Farma Tbk. | 288.13 Million USD | -310.225% |